The Experts below are selected from a list of 25893 Experts worldwide ranked by ideXlab platform
Ralph Weissleder - One of the best experts on this subject based on the ideXlab platform.
-
noninvasive Vascular Cell Adhesion molecule 1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:Background— Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1–targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. Methods and Results— In vivo phage display in apolipoprotein E–deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E–...
-
Noninvasive Vascular Cell Adhesion molecule-1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:BACKGROUND - Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1-targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. METHODS AND RESULTS - In vivo phage display in apolipoprotein E-deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E-deficient mice (n=28) after injection with VINP-28 or saline revealed signal enhancement in the aortic root of mice receiving VINP-28 (P
Peter Libby - One of the best experts on this subject based on the ideXlab platform.
-
noninvasive Vascular Cell Adhesion molecule 1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:Background— Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1–targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. Methods and Results— In vivo phage display in apolipoprotein E–deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E–...
-
Noninvasive Vascular Cell Adhesion molecule-1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:BACKGROUND - Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1-targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. METHODS AND RESULTS - In vivo phage display in apolipoprotein E-deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E-deficient mice (n=28) after injection with VINP-28 or saline revealed signal enhancement in the aortic root of mice receiving VINP-28 (P
-
pparα activators inhibit cytokine induced Vascular Cell Adhesion molecule 1 expression in human endothelial Cells
Circulation, 1999Co-Authors: Nikolaus Marx, Peter Libby, Tucker Collins, Galina K Sukhova, Jorge PlutzkyAbstract:Background—Adhesion molecule expression on the endothelial Cell (EC) surface is critical for leukocyte recruitment to atherosclerotic lesions. Better understanding of transcriptional regulation of Adhesion molecules in ECs may provide important insight into plaque formation. Peroxisome proliferator–activated receptor-α (PPARα), a member of the nuclear receptor family, regulates gene expression in response to certain fatty acids and fibric acid derivatives. The present study investigated PPARα expression in human ECs and their regulation of Vascular Cell Adhesion molecule-1 (VCAM-1). Methods and Results—Immunohistochemistry revealed that human carotid artery ECs express PPARα. Pretreatment of cultured human ECs with the PPARα activators fenofibrate or WY14643 inhibited TNF-α–induced VCAM-1 in a time- and concentration-dependent manner, an effect not seen with PPARγ activators. Both PPARα activators decreased cytokine-induced VCAM-1 mRNA expression without altering its mRNA half-life. Transient transfection...
Matthias Nahrendorf - One of the best experts on this subject based on the ideXlab platform.
-
noninvasive Vascular Cell Adhesion molecule 1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:Background— Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1–targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. Methods and Results— In vivo phage display in apolipoprotein E–deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E–...
-
Noninvasive Vascular Cell Adhesion molecule-1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:BACKGROUND - Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1-targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. METHODS AND RESULTS - In vivo phage display in apolipoprotein E-deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E-deficient mice (n=28) after injection with VINP-28 or saline revealed signal enhancement in the aortic root of mice receiving VINP-28 (P
Kimberly A. Kelly - One of the best experts on this subject based on the ideXlab platform.
-
noninvasive Vascular Cell Adhesion molecule 1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:Background— Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1–targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. Methods and Results— In vivo phage display in apolipoprotein E–deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E–...
-
Noninvasive Vascular Cell Adhesion molecule-1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:BACKGROUND - Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1-targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. METHODS AND RESULTS - In vivo phage display in apolipoprotein E-deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E-deficient mice (n=28) after injection with VINP-28 or saline revealed signal enhancement in the aortic root of mice receiving VINP-28 (P
Elena Aikawa - One of the best experts on this subject based on the ideXlab platform.
-
noninvasive Vascular Cell Adhesion molecule 1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:Background— Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1–targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. Methods and Results— In vivo phage display in apolipoprotein E–deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E–...
-
Noninvasive Vascular Cell Adhesion molecule-1 imaging identifies inflammatory activation of Cells in atherosclerosis
Circulation, 2006Co-Authors: Matthias Nahrendorf, David E Sosnovik, Kimberly A. Kelly, Peter Libby, Elena Aikawa, Farouc A. Jaffer, Ralph WeisslederAbstract:BACKGROUND - Noninvasive imaging of Adhesion molecules such as Vascular Cell Adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1-targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated Cells in human plaques. METHODS AND RESULTS - In vivo phage display in apolipoprotein E-deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1 internalizing nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all Cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E-deficient mice (n=28) after injection with VINP-28 or saline revealed signal enhancement in the aortic root of mice receiving VINP-28 (P
